625 related articles for article (PubMed ID: 31388135)
1. Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.
Baillie GS; Tejeda GS; Kelly MP
Nat Rev Drug Discov; 2019 Oct; 18(10):770-796. PubMed ID: 31388135
[TBL] [Abstract][Full Text] [Related]
2. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.
Ahmad F; Murata T; Shimizu K; Degerman E; Maurice D; Manganiello V
Oral Dis; 2015 Jan; 21(1):e25-50. PubMed ID: 25056711
[TBL] [Abstract][Full Text] [Related]
3. Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.
Sun J; Xiao Z; Haider A; Gebhard C; Xu H; Luo HB; Zhang HT; Josephson L; Wang L; Liang SH
J Med Chem; 2021 Jun; 64(11):7083-7109. PubMed ID: 34042442
[TBL] [Abstract][Full Text] [Related]
4. PDE inhibitors: a new approach to treat metabolic syndrome?
Lugnier C
Curr Opin Pharmacol; 2011 Dec; 11(6):698-706. PubMed ID: 22018840
[TBL] [Abstract][Full Text] [Related]
5. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
Kokkonen K; Kass DA
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase inhibitors.
Boswell-Smith V; Spina D; Page CP
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.
Wen RT; Zhang FF; Zhang HT
Psychopharmacology (Berl); 2018 Jun; 235(6):1793-1805. PubMed ID: 29663017
[TBL] [Abstract][Full Text] [Related]
8. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
Manganiello V
Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
[No Abstract] [Full Text] [Related]
9. The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.
Nadur NF; de Azevedo LL; Caruso L; Graebin CS; Lacerda RB; Kümmerle AE
Eur J Med Chem; 2021 Feb; 212():113123. PubMed ID: 33412421
[TBL] [Abstract][Full Text] [Related]
10. Basic and clinical characteristics of PDE 3 inhibitors as cardiotonic agents.
Endoh M
Cardiovasc Drugs Ther; 2007 Jun; 21(3):135-9. PubMed ID: 17508272
[No Abstract] [Full Text] [Related]
11. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
[TBL] [Abstract][Full Text] [Related]
12. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies.
Lerner A; Kim DH; Lee R
Leuk Lymphoma; 2000 Mar; 37(1-2):39-51. PubMed ID: 10721768
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.
Levy I; Horvath A; Azevedo M; de Alexandre RB; Stratakis CA
Curr Opin Pharmacol; 2011 Dec; 11(6):689-97. PubMed ID: 22047791
[TBL] [Abstract][Full Text] [Related]
14. cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases.
Martinez A; Gil C
Expert Opin Ther Pat; 2014 Dec; 24(12):1311-21. PubMed ID: 25284693
[TBL] [Abstract][Full Text] [Related]
15. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
16. Development of Phosphodiesterase-Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity.
Tulsian NK; Sin VJ; Koh HL; Anand GS
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34063491
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.
Souness JE; Aldous D; Sargent C
Immunopharmacology; 2000 May; 47(2-3):127-62. PubMed ID: 10878287
[No Abstract] [Full Text] [Related]
18. Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure.
Movsesian MA
Expert Opin Investig Drugs; 2000 May; 9(5):963-73. PubMed ID: 11060720
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.
Kim GE; Kass DA
Handb Exp Pharmacol; 2017; 243():249-269. PubMed ID: 27787716
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds.
Francis SH; Sekhar KR; Ke H; Corbin JD
Handb Exp Pharmacol; 2011; (200):93-133. PubMed ID: 20859794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
